Cargando…
Development of platelet replacement therapy using human induced pluripotent stem cells
In the body, platelets mainly work as a hemostatic agent, and the lack of platelets can cause serious bleeding. Induced pluripotent stem (iPS) cells potentially allow for a stable supply of platelets that are independent of donors and eliminate the risk of infection. However, a major challenge in iP...
Autores principales: | Nakamura, Sou, Sugimoto, Naoshi, Eto, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048793/ https://www.ncbi.nlm.nih.gov/pubmed/33507533 http://dx.doi.org/10.1111/dgd.12711 |
Ejemplares similares
-
Ex vivo generation of platelet products from human iPS cells
por: Nakamura, Sou, et al.
Publicado: (2020) -
Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell‐Derived Platelets
por: Hirata, Shinji, et al.
Publicado: (2016) -
Generation and manipulation of human iPSC-derived platelets
por: Sugimoto, Naoshi, et al.
Publicado: (2021) -
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets
por: Chen, Si Jing, et al.
Publicado: (2022) -
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
por: Takayama, Naoya, et al.
Publicado: (2010)